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Peripartum sepsis is still a concern in Obstetrics and Gynecol-
ogy in 2018. Sepsis is associated with significant morbidity in
obstetric population and is one of the major causes of mater-
nal mortality (1). Although universally agreed definition for
maternal sepsis is lacking, the European Society of Intensive
Care Medicine and the Society of Critical Care Medicine
defines sepsis as life-threatening organ dysfunction caused by
a dysregulated host response to infection (2).
Timely diagnosis and early initiation with intravenous
antibiotic treatment are the key elements for successful man-
agement of severe infections. The mortality associated with
sepsis is >10% and septic shock >30%. This is also the case
in Obstetrics and Gynecology. It is thought that half of the
fatal cases of puerperal sepsis can be prevented with early
detection of septic condition (1).
The rate of serious sepsis is 1.8 per 1000 pregnant women
in Europe (3). In a recently reported study 17% of sepsis were
diagnosed antepartum, 36% intrapartum and 47% were diag-
nosed in the postpartum period (3). The source of infection
was most often the genital tract (61%), followed by the uri-
nary tract in 25% of cases (3). Maternal sepsis was also a risk
for the fetus, as it was associated with an increased risk of
preterm delivery (OR 2.8), and a high perinatal mortality rate
(OR 5.8) (3).
Another US study indicates that the incidence of postop-
erative sepsis is increasing and up to 1% may develop septic
symptoms after elective surgery (4). Infective complications
are associated with common operations, after hysterectomy
surgical site infection rate is 2%, more severe deep or organ
space surgical site infection account up to 1%. Risk factors
for severe infectious complications include high BMI,
advanced age and smoking. However, in one study with hys-
terectomy, deep surgical site infections were associated with
younger age, longer surgical times, gynecological cancer and
open hysterectomy (5). Post-operative peritonitis is a life-
threatening intra-abdominal infection with high rates of
mortality (5). The diagnosis of an intra-abdominal infection
is primarily based on clinical assessment and high suspicion.
The symptoms of sepsis may be nonspecific in young and
previously healthy patients. However, the patient is typically
admitted to the emergency department with abdominal pain
and a systemic inflammatory response, including fever/hy-
pothermia, tachycardia, and tachypnea. Abdominal rigidity
suggests the presence of peritonitis. Signs of hypotension and
hypo-perfusion such as oliguria, acute alteration of mental
status and lactic acidosis are indicative of ongoing sepsis.
Diagnostic imaging is often insufficient in the early stage.
Traditional biomarkers C-reactive protein (CRP) and
white cell count can be used for the diagnosis of bacterial
infection and antibiotic treatment monitoring, but they seem
to be moderately outperformed by a more recently intro-
duced biomarker procalcitonin (PCT). The latent period of
approximately 6 h of CRP is significantly slower than that
for PCT. CRP is non-specific in diagnosis of sepsis, but has
a high negative predictive value. Leucocyte count is increased
during pregnancy, which limits its use as infection/inflamma-
tion biomarker. More accurate biomarkers are welcome.
Procalcitonin is a serum pro-hormone that increases dur-
ing body response to tissue injury, systemic inflammation
and particularly, in the presence of severe bacterial infection.
PCT is released from various tissues as a response to endo-
toxins and pro-inflammatory mediators. As PCT concentra-
tion in the blood increases significantly within the first hours
in severe bacterial infections (latent period of 2–4 h), it can
be used for the differential diagnosis of conditions requiring
early antibiotic treatment. PCT measurements are also used
for the follow-up of the treatment response as its concentra-
tion in blood decreases relatively quickly as the infection
resolves (PCT plasma half-life is around 25 h) (6).
Procalcitonin is more sensitive and specific for bacterial
infection while CRP is a more universal marker of any
inflammation (6). In the early phase of an extensive bacterial
infection, and reflecting variable microbial etiology, PCT and
CRP values may not behave analogously. PCT could be an
especially useful biomarker in gram-negative infections as the
rise of PCT is often more significant than that in gram-posi-
tive bloodstream infections. Gram-negative E. Coli is the
most common pathogen in blood cultures in severe obstetric
infections (3).
Quantitative estimation of PCT is useful. Systemic infec-
tion (sepsis) is unlikely with PCT level of <0.5 lg/L (7). A
level of 0.5–2.0 lg/L indicates possible systemic sepsis, 2.0–
10.0 lg/L suggests that systemic infection (sepsis) likely and
PCT levels of >10.0 lg/L indicate severe bacterial infection,
almost always bacterial sepsis or septic shock. Studies have
also indicated that the change in PCT values (delta-PCT)
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might be more useful for diagnosing infection than single
PCT measurements.
The use of PCT has been evaluated for the decision to stop
antibiotic treatment. A recent meta-analysis confirms that
PCT can be a feasible biomarker for the reduction of con-
sumption and duration of antibiotics for septic patients (7).
This has also been shown in newborns with early-onset sepsis
(8). One of the strengths of using PCT is that it seems to be a
useful tool to guide and monitor antibiotic therapy. A decrease
of PCT ≥80% from peak value, or PCT ≤0.5 lg/L are com-
monly used criteria for stopping antibiotics (7). However, data
in non-pregnant women should be extrapolated with caution
to pregnant women and further prospective data are needed. A
retrospective analysis indicated that the sensitivity and speci-
ficity of PCT is superior to CRP for the diagnosis of intrauter-
ine infections in pregnant women with pre-labor rupture of
membranes (9).
In newborns PCT seems to have predictive value for
detection of neonatal sepsis. In a recent Norwegian study
PCT was superior to CRP, white blood cell count and plate-
let count (10). High predictive value of PCT for early onset
neonatal sepsis was found in another study. High maternal
PCT predicted neonatal sepsis with >85% sensitivity, 87%
specificity, 85% positive predictive value and 87% negative
predictive value (11). However, reference values for PCT in
pregnancy have not been established and PCT levels should
always be considered on an individual patient level, taking in
account the clinical condition of the patient.
In Finnish national Current Guideline for sepsis endorse
the use of PCT in clinical practice to diagnose and monitor
the treatment response in septic patients. A recent nation-
wide survey from Finland shows that the adherence to this
guideline is variable and that use of PCT has not been estab-
lished. The tertiary-care hospital that had highest number of
PCT measurements in Finland in 2014 and 2015 used PCT
mostly for monitoring antibiotic treatment. Hospitals with
modest use of PCT, used it most often for diagnostics.
In conclusion, PCT seems to be a useful biomarker for
severe bacterial infections and this is likely to be the case
also in Obstetrics and Gynecology. PCT can also be used in
the guidance of antibiotic therapy. Optimising antibiotic
therapy is important on an individual-patient level but can
also minimise emergence of antibiotic resistance. More data
are needed to support the use of PCT in Obstetrics and
Gynecology. A recent Cochrane Review concluded that the
available evidence is moderate quality, with insufficient
sample power per outcome. This review does not support
the use of PCT-guided antimicrobial therapy of patients
with septic conditions (12). Maternal sepsis rate is increas-
ing (3) and severe infection is a significant gynecological
complication. Traditional inflammation markers such as
CRP and white blood cell count may be more familiar to
many. However, new, more sensitive and specific biomark-
ers such as PCT may be more useful for the diagnosis and
monitoring of patients with gynecologic operations and
postpartum infections.
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